1. Generics Bulletin
  2. >>Business
  3. >>Strategy

No 'Constraining Situation' On Generic Vascepa API, Says Strides MD

Q3 Revenues Jump; Generic Suprep Likely To Be Launched In Q4

 
• By Vibha Ravi

Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business.

Earnings Concept
Strides Reported A Strong Third Quarter And Expects Generic Vascepa To Add Momentum • Source: Shutterstock

Strides Pharma Science founder and managing director Arun Kumar said he does not see a “constraining situation” for supplies of the active pharmaceutical ingredients to manufacture a generic to Amarin’s only commercialized product to date Vascepa (icosapent ethyl).

US marketing partner Amneal Pharmaceuticals, Inc. launched the product in the third quarter of fiscal year 2023-24 after Strides...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By Dave Wallace

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Three’s A Crowd? Celltrion Launches Denosumab In US

 
• By Dave Wallace

A third pair of Prolia and Xgeva rivals has now been launched in the US, with Celltrion throwing its hat into the ring after denosumab launches by Sandoz and Fresenius Kabi. But this is only the beginning for what is shaping up to be another highly competitive biosimilars market.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Collating data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?